dual acting LKB1-AMPK activators/B-Raf inhibitors (Columbia University/Massachusetts General Hospital)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug Namedual acting LKB1-AMPK activators/B-Raf inhibitors (Columbia University/Massachusetts General Hospital)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAMP-activated protein kinases activatorsSerine/threonine-protein kinase B-raf inhibitorsSerine/threonine-protein kinase STK11 stimulants
TargetsSerine/threonine-protein kinase STK11Serine/threonine-protein kinase B-rafAMP-activated protein kinases
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesColumbia University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe General Hospital Corporation D/B/A Massachusetts General HospitalColumbia University
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A